Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash from Financing Activities (2020 - 2025)

Agilon Health (AGL) has disclosed Cash from Financing Activities for 6 consecutive years, with -$17000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 22.73% year-over-year to -$17000.0, compared with a TTM value of -$3.0 million through Dec 2025, down 15.91%, and an annual FY2025 reading of -$3.0 million, down 15.91% over the prior year.
  • Cash from Financing Activities was -$17000.0 for Q4 2025 at Agilon Health, up from -$236000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.1 billion in Q2 2021 and bottomed at -$202.0 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $49.2 million, with a median of $727500.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 26688.13% in 2021, then tumbled 4788.72% in 2023.
  • Year by year, Cash from Financing Activities stood at $10.4 million in 2021, then crashed by 89.15% to $1.1 million in 2022, then crashed by 174.78% to -$845000.0 in 2023, then skyrocketed by 97.4% to -$22000.0 in 2024, then increased by 22.73% to -$17000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for AGL at -$17000.0 in Q4 2025, -$236000.0 in Q3 2025, and -$2.6 million in Q2 2025.